Comera Life Sciences Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMRA research report →
Companycomeralifesciences.com
Comera Life Sciences Holdings, Inc. , a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
- CEO
- Michael G. Campbell
- IPO
- 2020
- Employees
- 12
- HQ
- Woburn, MA, US
Price Chart
Valuation
- Market Cap
- $3.07K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 66.77%
- Op Margin
- -1890.69%
- Net Margin
- -2843.79%
- ROE
- 47452.88%
- ROIC
- 1768.56%
Growth & Income
- Revenue
- $633.10K · 97.95%
- Net Income
- $-18,004,098 · -230.24%
- EPS
- $-1.76 · -506.90%
- Op Income
- $-11,970,015
- FCF YoY
- -151.29%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -20.43
- Avg Volume
- 806.188
Get TickerSpark's AI analysis on CMRA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 29, 23 | Konar Shameek | buy | 4,090,908 |
| Dec 29, 23 | Konar Shameek | buy | 0 |
| Dec 27, 23 | Konar Shameek | other | 0 |
| Sep 11, 23 | Konar Shameek | other | 513,447 |
| Dec 29, 23 | DENNY GEORGE P III | buy | 3,913,526 |
| Dec 29, 23 | DENNY GEORGE P III | buy | 0 |
| Dec 27, 23 | DENNY GEORGE P III | other | 0 |
| Sep 11, 23 | DENNY GEORGE P III | other | 337,408 |
| Jan 4, 23 | DENNY GEORGE P III | other | 405,405 |
| Dec 27, 23 | HALPERN JOHN D | other | 0 |
Our CMRA Coverage
We haven't published any research on CMRA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CMRA Report →